Nephrology News
Upfront Cabozantinib for Advanced RCC Improves Outcomes
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
By accepting you will be accessing a service provided by a third-party external to https://www.galencarepartners.com/